Showing results (1861-1870 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Inhibition of in vitro LAK generation by OK-432M Yagita, E A Grimm
Cancer Immunology, Immunotherapy : CII|January 11, 2022
Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapyRyuhei Okada, Takuya Kato, Aki Furusawa, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cellsL V Levin, T W Griffin, L R Childs, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Impaired T- and B-cell functions in patients with Hodgkin's disease. Reduced mitogenic responsibility and Il-2 production is not caused by defective CD4+-cellsL Bergmann, P S Mitrou, M Demmer-Dieckmann, et al.
Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2022
Oral administration of a whole glucan particle (WGP)-based therapeutic cancer vaccine targeting macrophages inhibits tumor growthLiuyang He, Yu Bai, Lei Xia, et al.
Cancer Immunology, Immunotherapy : CII|March 13, 2021
Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancerShu-Fen Chiang, Kevin Chih-Yang Huang, William Tzu-Liang Chen, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual diseaseR R Salup, R H Wiltrout
Cancer Immunology, Immunotherapy : CII|March 10, 2021
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyteBaojuan Han, Lina Dong, Jing Zhou, et al.
Cancer Immunology, Immunotherapy : CII|November 2, 2022
Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activityJohannes Lutz, Michael Meister, Mohamed Habbeddine, et al.
Pageof 652